Digestion
Original Paper
Acute Hepatic Failure following Transcatheter Arterial Embolization for the Treatment of Hepatocellular CarcinomaKatsushima S.a · Inokuma T.a · Oi H.b · Okamura J.c · Higashi T.d · Takeuchi R.d · Hidaka A.d · Shigeno C.d · Iida Y.a · Konishi J.daFirst Department of Internal Medicine, bDepartment of Radiology, and cDepartment of Surgery, Osaka Teishin Hospital, Osaka, and dDepartment of Radiology and Nuclear Medicine, Kyoto University School of Medicine, Kyoto, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: June 23, 1995
Accepted: April 10, 1996
Published online: February 05, 2009
Issue release date: 1997
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)
For additional information: https://www.karger.com/DIG
Abstract
We conducted a retrospective analysis to evaluate the risk factors associated with the occurrence of acute hepatic failure following transcatheter arterial embolization (TAE) for hepatocellular carcinoma. From 1984 to 1993 we performed a total of 623 embolization procedures in 369 patients with both hepatocellular carcinoma and chronic liver disease. Within 2 weeks after TAE, 13 patients (2.1%) experienced hepatic failure as characterized by a rapid increase in serum bilirubin levels and the development of hepatic encephalopathy of grade 2 or higher. These results indicated that the following are risk factors for acute hepatic failure after TAE: poor hepatic functional reserve; high-dose infusion of chemotherapeutic agents, and a history of multiple embolization procedures.
© 1997 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Received: June 23, 1995
Accepted: April 10, 1996
Published online: February 05, 2009
Issue release date: 1997
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)
For additional information: https://www.karger.com/DIG
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission